An ADHD diagnosis means a person is prone to impulsivity and distractibility, which can manifest in the form of substance misuse, traffic accidents, criminality and even suicidal behavior. A recent ...

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.

Treatment linked to reduced rates of first occurrence of suicidal behaviors, substance misuse, transport accidents, criminality. HealthDay News — Attention-deficit ...

Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta® ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

Hyderabad-based Granules Pharmaceuticals has received tentative approval from the US Food and Drug Administration (FDA) for its generic Attention Deficit Hyperactivity Disorder (ADHD) medication. The ...

Millions of Americans who rely on medication to manage attention deficit hyperactivity disorder (ADHD) may be impacted by a new nationwide drug recall. Sun Pharmaceutical Industries has issued a ...

After more than 50 years leading the fight to legitimize attention deficit hyperactivity disorder, Keith Conners could be celebrating. Severely hyperactive and impulsive children, once shunned as bad ...

The study included participants taking ADHD drug treatment (56.7%), and the researchers found this was associated with significantly reduced rates of suicidal behaviors, substance misuse, transport ...